摘要
目的:探索TRAIL基因转染内皮祖细胞对肝癌的治疗作用.方法:通过PCR扩增TRAIL基因,将TRAIL基因与pcDNA3.1载体连接,采用腺病毒转染入内皮祖细胞中,并用Western blot进行TRAIL基因的表达鉴定.建立小鼠皮下移植瘤动物模型,用携带TRAIL基因的重组腺病毒转染内皮祖细胞,经尾静脉注射,同时以生理盐水和空载腺病毒为对照,分别观察治疗效果.结果:经酶切及测序鉴定,TRAIL基因与pcDNA3.1的重组质粒构建成功.Western blot检测发现TRAIL基因转染入内皮祖细胞后有表达.转染TRAIL基因组的抑瘤率为47.77%,肿瘤体积平均值为0.791cm3±0.119cm3,肿瘤质量平均值为0.29g±0.04g,经统计学分析与对照组有显著性差异.结论:TRAIL基因成功转染入内皮祖细胞并表达,TRAIL基因转染内皮祖细胞可以明显抑制H22移植瘤的生长,且无明显不良反应.
AIM：To investigate the in uence of intravenous administration of endothelial progenitor cells（EPCs） transfected with the TRAIL gene on the growth of tumors derived from subcutaneously inoculated H22 cells in nude mice to provide a theoretical basis for the treatment of liver cancer.METHODS：The TRAIL gene was amplified by PCR,cloned into the pcDNA3.1 vector,and transfected into EPCs.The expression of TRAIL protein was detected by Western blot.Mice were inoculated subcutaneously with H22 cells to induce tumor formation.Tumor-bearing mice were randomly divided into three groups and injected via the tail vein with EPCs transfected with the recombinant adenoviral vector carrying the TRAIL gene,the empty vector,and normal saline,respectively.RESULTS：Restriction enzyme digestion and DNA sequencing analyses indicate that the recombinant plasmid was constructed success-fully.TRAIL expression was detected in EPCs transfected with the recombinant adenoviral vector by Western blot.The rate of reduced tu-mor growth was 47.77% in mice administered with EPCs carrying the TRAIL gene.Tumor vol-ume and weight in the experimental group（0.791 cm3 ± 0.119 cm3,0.29 g ± 0.04 g） were signifi cant-ly lower than those in the two control groups（all P 0.05）.CONCLUSION：The recombinant plasmid car-rying the TRAIL gene has been successfully con-structed.Intravenous administration of endothe-lial progenitor cells transfected with the TRAIL gene inhibits the growth of tumors derived from H22 cells in nude mice.
出处
《世界华人消化杂志》
CAS
北大核心
2012年第31期2986-2991,共6页
World Chinese Journal of Digestology
基金
国家自然科学基金资助项目
No.30972904
江苏省六大人才高峰基金资助项目~~
